Skip to main content

Drug Interactions between baricitinib and Dristan Sinus

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ibuprofen baricitinib

Applies to: Dristan Sinus (ibuprofen / pseudoephedrine) and baricitinib

MONITOR: Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation. Patients with a prior history of peptic ulceration or diverticular disease may also have an increased risk. Adverse events of diverticulitis and GI perforation have been infrequently reported in clinical studies and postmarketing use of JAK inhibitors such as baricitinib, ruxolitinib, tofacitinib, and upadacitinib. However, the role of JAK inhibition in these events has not been determined. In studies with rheumatoid arthritis and ulcerative colitis patients, many were receiving background therapy with NSAIDs or corticosteroids.

MANAGEMENT: Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids. Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.

References

  1. Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT (2011) "Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding." Gastroenterology, 140, p. 1427-33
  2. Medicines and Healthcare products Regulatory Agency (2020) Baricitinib (Olumiant¥): increased risk of diverticulitis, particularly in patients with risk factors. https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors
  3. (2021) "Product Information. Olumiant (bARICITinib)." Eli Lilly Australia Pty Ltd, vA7_April2021
  4. (2023) "Product Information. Olumiant (baricitinib)." Eli Lilly and Company Ltd
  5. Hoisnard L, Lebrun-Vignes B, Maury S, et al. (2022) "Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database." Sci Rep, 12, p. 7140
  6. (2023) "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company
  7. (2023) "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group
  8. (2023) "Product Information. Xeljanz (tofacitinib)." Pfizer Ltd
  9. (2023) "Product Information. Xeljanz (tOFACitinib)." Pfizer Australia Pty Ltd, pfpxelja10423
  10. (2023) "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC
  11. (2023) "Product Information. Rinvoq (upadacitinib)." AbbVie Ltd
  12. (2023) "Product Information. Rinvoq (upadacitinib)." AbbVie Pty Ltd, 8
  13. (2022) "Product Information. Olumiant (baricitinib)." Eli Lilly Canada Inc, 260967
  14. (2022) "Product Information. Xeljanz (tofacitinib)." Pfizer Canada ULC, 258173
  15. (2022) "Product Information. Rinvoq (upadacitinib)." AbbVie Corporation, 262176
View all 15 references

Switch to consumer interaction data

Drug and food interactions

Moderate

ibuprofen food

Applies to: Dristan Sinus (ibuprofen / pseudoephedrine)

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn

Switch to consumer interaction data

Moderate

pseudoephedrine food

Applies to: Dristan Sinus (ibuprofen / pseudoephedrine)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References

  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company
View all 7 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.